Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

Integrative oncology interest in persons with a cancer diagnosis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...

Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...

Ultima Genomics, Inc., a developer of ultra-high-throughput sequencing systems, continues its mission to enable sequencing at scale with the unveiling of the UG200 Series and next generation Solaris 2 ...